As Gilead’s HIV, HCV Hull Leaks In Q4, Veklury Plugs Holes
No Signs Of Variant Strain Resistance To Remdesivir
Sales of COVID-19 drug Veklury helped keep sales in the black as the pandemic and generic competition weighed on HIV and HCV products; Gilead raised full-year 2021 guidance.
You may also be interested in...
COVID-19 doesn't seem to be going away any time soon and antivirals remdesivir and favipiravir remain part of the treatment armamentarium. “Safety inventories” are in place for remdesivir in India, while a key physician anticipates an uptick in the use of favipiravir amid a surge in cases in some parts of the country.
Pandemic Perspectives: US FDA ACTT’s On Its Faith In Randomized Trials With Veklury Approval Despite WHO Study
US FDA has not deviated from its bedrock trust in the value of ‘statistically reliable’ endpoints amidst the COVID-19 pandemic, the Pink Sheet’s Drug Review Profile of Gilead’s Veklury shows.
The company's specialty franchises are on track for solid growth but the North American generics outlook remains lackluster.